Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 3/20 | 0.39 |
| ▸ | RXRB | P28702 | 3/20 | 0.39 |
| ▸ | RXRG | P48443 | 3/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372375 | 1.00 | ADORA1 (0.46) | ADORA1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6223187 | 0.95 | ADORA1 (0.45) | ADORA1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6220910 | 0.92 | KDM4E (0.44) | ADORA1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6224664 | 0.91 | KDM4E (0.43) | ADORA1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6223285 | 0.91 | KDM4E (0.45) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6221221 | 0.90 | ADORA1 (0.47) | ADORA1KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL6792756 | 0.90 | ADORA1 (0.47) | ADORA1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6220833 | 0.90 | KDM4E (0.44) | ADORA1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6222464 | 0.90 | KDM4E (0.42) | ADORA1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6220853 | 0.89 | KDM4E (0.46) | ADORA1KDM4EALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685849-B1 | PDE 4 INHIBITORS FOR THE TREATMENT OF INTERSTITIAL CYSTITIS | ASTELLAS PHARMA INC (JP) | 2012-01-25 | — | — | EP | claimed |
| US-20070167450-A1 | Agent for treating chronic pelvic pain syndrome | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | claimed |
| EP-1685849-A1 | REMEDY FOR CHRONIC PELVIC PAIN SYNDROME | Astellas Pharma Inc. (JP) | 2006-08-02 | — | — | EP | claimed |
| EP-1225173-B1 | NAPHTHYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2005-09-28 | — | — | EP | claimed |
| US-6740662-B1 | HAVING 2-OXO-1,2-DIHYDRO- FUNCTIONALITY; PHOSPHODIESTERASE INHIBITORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-25 | — | — | US | claimed |
| CN-1148369-C | 1,8-naphthyridine derivatives | ֮����ҩ��ʽ���� | 2004-05-05 | — | — | CN | claimed |
| CN-1382141-A | 1,8-naphthyridine derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2002-11-27 | — | — | CN | claimed |
| EP-1225173-A1 | NAPHTHYRIDINE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-07-24 | — | — | EP | claimed |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | GLAS USA LLC | 2021-02-04 | — | — | US | disclosed |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
| WO-2019246317-A9 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | PROGENITY, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2019147824-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PROGENITY, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019036382-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | PROGENITY INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-1486204-A1 | POWDERY MEDICINAL COMPOSITIONS FOR INHALATION AND PROCESS FOR PRODUCING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20040184995-A1 | Novel dry powder inhalation for lung-delivery and manufacturing method thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| US-6740662-B1 | HAVING 2-OXO-1,2-DIHYDRO- FUNCTIONALITY; PHOSPHODIESTERASE INHIBITORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-25 | — | — | US | disclosed |
| CN-1148369-C | 1,8-naphthyridine derivatives | ֮����ҩ��ʽ���� | 2004-05-05 | — | — | CN | disclosed |
| CN-1382141-A | 1,8-naphthyridine derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2002-11-27 | — | — | CN | disclosed |
| EP-1225173-A1 | NAPHTHYRIDINE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | ADORA1 2391/4885KDM4E 1259/4885ALDH1A1 2119/4885 |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | ADORA1 3616/4885KDM4E 2618/4885ALDH1A1 3155/4885 |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | ADORA1 563/4885KDM4E 2278/4885ALDH1A1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.